Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia
Lian Xu(Huazhong Agricultural University), Steven P. Treon(Dana-Farber Cancer Institute), Zachary R. Hunter(Harvard University), Christopher J. Patterson(Dana-Farber Cancer Institute), Amanda Kofides(Shaanxi Research Association for Women and Family), Maria Demos(Shaanxi Research Association for Women and Family), Nicholas Tsakmaklis(Shaanxi Research Association for Women and Family), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Richard R. Furman(Cornell University), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Jiaji G. Chen(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Xia Liu(Dana-Farber Cancer Institute), Ranjana H. Advani(Stanford Medicine), Jorge J. Castillo(Dana-Farber Cancer Institute)
Cited by 138
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k